These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 33078386)

  • 1. Fenfluramine HCl (Fintepla
    Sullivan J; Scheffer IE; Lagae L; Nabbout R; Pringsheim M; Talwar D; Polster T; Galer B; Lock M; Agarwal A; Gammaitoni A; Morrison G; Farfel G
    Epilepsia; 2020 Nov; 61(11):2396-2404. PubMed ID: 33078386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fenfluramine for Treatment-Resistant Seizures in Patients With Dravet Syndrome Receiving Stiripentol-Inclusive Regimens: A Randomized Clinical Trial.
    Nabbout R; Mistry A; Zuberi S; Villeneuve N; Gil-Nagel A; Sanchez-Carpintero R; Stephani U; Laux L; Wirrell E; Knupp K; Chiron C; Farfel G; Galer BS; Morrison G; Lock M; Agarwal A; Auvin S;
    JAMA Neurol; 2020 Mar; 77(3):300-308. PubMed ID: 31790543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular safety of fenfluramine in the treatment of Dravet syndrome: Analysis of an ongoing long-term open-label safety extension study.
    Lai WW; Galer BS; Wong PC; Farfel G; Pringsheim M; Keane MG; Agarwal A
    Epilepsia; 2020 Nov; 61(11):2386-2395. PubMed ID: 32809271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial.
    Lagae L; Sullivan J; Knupp K; Laux L; Polster T; Nikanorova M; Devinsky O; Cross JH; Guerrini R; Talwar D; Miller I; Farfel G; Galer BS; Gammaitoni A; Mistry A; Morrison G; Lock M; Agarwal A; Lai WW; Ceulemans B;
    Lancet; 2019 Dec; 394(10216):2243-2254. PubMed ID: 31862249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved everyday executive functioning following profound reduction in seizure frequency with fenfluramine: Analysis from a phase 3 long-term extension study in children/young adults with Dravet syndrome.
    Bishop KI; Isquith PK; Gioia GA; Gammaitoni AR; Farfel G; Galer BS; Nabbout R; Wirrell EC; Polster T; Sullivan J
    Epilepsy Behav; 2021 Aug; 121(Pt A):108024. PubMed ID: 34023810
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: A real-world study.
    Specchio N; Pietrafusa N; Doccini V; Trivisano M; Darra F; Ragona F; Cossu A; Spolverato S; Battaglia D; Quintiliani M; Luigia Gambardella M; Rosati A; Mei D; Granata T; Dalla Bernardina B; Vigevano F; Guerrini R
    Epilepsia; 2020 Nov; 61(11):2405-2414. PubMed ID: 32945537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of fenfluramine in patients with Dravet syndrome: A meta-analysis.
    Zhang L; Li W; Wang C
    Acta Neurol Scand; 2021 Apr; 143(4):339-348. PubMed ID: 33336426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term cardiovascular safety of fenfluramine in patients with Dravet syndrome treated for up to 3 years: Findings from serial echocardiographic assessments.
    Agarwal A; Farfel GM; Gammaitoni AR; Wong PC; Pinto FJ; Galer BS
    Eur J Paediatr Neurol; 2022 Jul; 39():35-39. PubMed ID: 35640431
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fenfluramine provides clinically meaningful reduction in frequency of drop seizures in patients with Lennox-Gastaut syndrome: Interim analysis of an open-label extension study.
    Knupp KG; Scheffer IE; Ceulemans B; Sullivan J; Nickels KC; Lagae L; Guerrini R; Zuberi SM; Nabbout R; Riney K; Agarwal A; Lock M; Dai D; Farfel GM; Galer BS; Gammaitoni AR; Polega S; Davis R; Gil-Nagel A
    Epilepsia; 2023 Jan; 64(1):139-151. PubMed ID: 36196777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Don't Fear the Reefer-Evidence Mounts for Plant-Based Cannabidiol as Treatment for Epilepsy.
    Perry MS
    Epilepsy Curr; 2019; 19(2):93-95. PubMed ID: 30955420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-dose fenfluramine significantly reduces seizure frequency in Dravet syndrome: a prospective study of a new cohort of patients.
    Schoonjans A; Paelinck BP; Marchau F; Gunning B; Gammaitoni A; Galer BS; Lagae L; Ceulemans B
    Eur J Neurol; 2017 Feb; 24(2):309-314. PubMed ID: 27790834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fenfluramine: A Review in Dravet and Lennox-Gastaut Syndromes.
    Frampton JE
    Drugs; 2023 Jul; 83(10):923-934. PubMed ID: 37316680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative efficacy and safety of stiripentol, cannabidiol and fenfluramine as first-line add-on therapies for seizures in Dravet syndrome: A network meta-analysis.
    Guerrini R; Chiron C; Vandame D; Linley W; Toward T
    Epilepsia Open; 2024 Apr; 9(2):689-703. PubMed ID: 38427284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An examination of the efficacy and safety of fenfluramine in adults, children, and adolescents with Dravet syndrome in a real-world practice setting: A report from the Fenfluramine European Early Access Program.
    Guerrini R; Specchio N; Aledo-Serrano Á; Pringsheim M; Darra F; Mayer T; Gil-Nagel A; Polster T; Zuberi SM; Lothe A; Gammaitoni A; Strzelczyk A
    Epilepsia Open; 2022 Dec; 7(4):578-587. PubMed ID: 35801621
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose-Ranging Effect of Adjunctive Oral Cannabidiol vs Placebo on Convulsive Seizure Frequency in Dravet Syndrome: A Randomized Clinical Trial.
    Miller I; Scheffer IE; Gunning B; Sanchez-Carpintero R; Gil-Nagel A; Perry MS; Saneto RP; Checketts D; Dunayevich E; Knappertz V;
    JAMA Neurol; 2020 May; 77(5):613-621. PubMed ID: 32119035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A pilot, open-label study of the effectiveness and tolerability of low-dose ZX008 (fenfluramine HCl) in Lennox-Gastaut syndrome.
    Lagae L; Schoonjans AS; Gammaitoni AR; Galer BS; Ceulemans B
    Epilepsia; 2018 Oct; 59(10):1881-1888. PubMed ID: 30146701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fenfluramine significantly reduces day-to-day seizure burden by increasing number of seizure-free days and time between seizures in patients with Dravet syndrome: A time-to-event analysis.
    Sullivan J; Specchio N; Devinsky O; Auvin S; Perry MS; Strzelczyk A; Gil-Nagel A; Dai D; Galer BS; Gammaitoni AR
    Epilepsia; 2022 Jan; 63(1):130-138. PubMed ID: 34676542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Five-year extended follow-up status of 10 patients with Dravet syndrome treated with fenfluramine.
    Ceulemans B; Schoonjans AS; Marchau F; Paelinck BP; Lagae L
    Epilepsia; 2016 Jul; 57(7):e129-34. PubMed ID: 27197941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term cannabidiol treatment in patients with Dravet syndrome: An open-label extension trial.
    Devinsky O; Nabbout R; Miller I; Laux L; Zolnowska M; Wright S; Roberts C
    Epilepsia; 2019 Feb; 60(2):294-302. PubMed ID: 30582156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative short-term efficacy and safety of add-on anti-seizure medications in Dravet syndrome: An indirect treatment comparison.
    Devi N; Madaan P; Asrar MM; Sahu JK; Bansal D
    Seizure; 2021 Oct; 91():316-324. PubMed ID: 34274891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.